Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Antibodies against programmed death (PD) pathway are revolutionizing cancer immunotherapy. Currently five antibodies against PD-1/PD-L1 have been approved. The clinical use of these antibodies is rapidly expan...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Bingshan Liu, Yongping Song and Delong Liu Tags: Review Source Type: research